Browsing “HSI Market Alert | EVERSANA”

ICER’s Dramatic Shift from QALY to Pharma Profit Metrics Could Have a Chilling Effect on Innovation

The Institute for Clinical and Economic Review (ICER) has been very responsive to the current public health pandemic, from adjusting their review timelines to assessing COVID-19 impact on drug pricing and patient access. Within a few days of Gilead’s remdesivir gaining emergency approval by the U.S. Food and Drug Administration (FDA), ICER has published an […]

SPOPTIMIZER by EVERSANA™

Optimize Your Specialty Pharmacy Choices​ SPOPTIMIZER is the only objective online platform that ranks eighty-five specialty pharmacy candidates targeted for current and future network needs based upon key service capabilities and organizational attributes. Interactive Web-Based Tool Identify specific Specialty Pharmacy candidates targeted for current and future network needs based upon key service capabilities and organizational attributes […]

ICER Indefinitely Postpones Public Meetings for Sickle Cell Disease and Cystic Fibrosis; Expands Other Assessment Timelines Up to Three Months

BOSTON, March 18, 2020 – The Institute for Clinical and Economic Review (ICER) today announced several changes to its timelines for upcoming assessments. ICER’s review process involves significant engagement across a variety of external stakeholders — health care providers, life sciences companies, health insurers, and patient advocacy groups — the same types of organizations that […]

Express Scripts and Prime Therapeutics Collaborate to Drive Down Pharmaceutical Costs

What happened? On December 19, 2019 Express Scripts and Prime Therapeutics announced a new three-year collaboration that they hope will drive down pharmacy costs for members and clients. Express Scripts, acquired by Cigna in December 2018, will provide its retail pharmacy network and negotiate biopharmaceutical contracts for products covered under the pharmacy benefit on behalf […]